DIA’s Annual Canadian Meeting: Thinking Globally, Acting Locally for The Well-Being of the Patient

With the expiration of numerous patents for originator biologicals and the development of follow-on products, the market for biosimilars is growing at a rapid pace. These biosimilars and follow-on biologics have garnered interest for their cost-effective benefits in patient care but questions remain about many aspects of “similarity." As biosimilars become more available to patients, there are important factors for patients and health care providers that must be addressed. This session will focus on the innovations, technologies, and regulatory information surrounding biosimilars

Topics to be covered include Canadian and US Regulatory Developments, Interchangeability, Labeling, Naming, and Extrapolation and will be reviewed from various perspectives.